CytoGen, Inc.

As of June 30, 2026, CytoGen, Inc. carries a market capitalization of 72.85B, placing it among publicly traded companies globally. Its enterprise value stands at 65.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, CytoGen, Inc. has 23.13M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.66, and the price-to-book ratio stands at 2.18.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 65.05B versus a market cap of 72.85B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, CytoGen, Inc. maintains a current ratio of 7.49, meaning it holds 7.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.27, indicating elevated leverage, while an interest coverage ratio of -1.70 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, CytoGen, Inc. posted a negative return on equity (ROE) of -27.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -17.13, reflecting losses generated across the asset base. The company generates approximately 655.91M in revenue per employee across its workforce of 41.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.80 indicates how many times CytoGen, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, CytoGen, Inc. recorded an income tax benefit of -564.09M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -11.11B and -10.55B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, CytoGen, Inc.'s stock has declined approximately 23.28% over the past 52 weeks. The 50-day moving average sits at 3,084.20, while the 200-day moving average is 4,621.55.

Over the twelve months ended June 30, 2026, CytoGen, Inc. generated 27.38B in revenue and converted that into -10.55B in net income, yielding earnings per share of -456.55. EBITDA reached -3.78B, while operating income came in at -5.87B.

As of June 30, 2026, CytoGen, Inc. holds 22.42B in cash and equivalents against 14.27B in total debt, resulting in a net debt position of -1.78B. Total book value stands at 33.40B, with working capital of 29.24B providing operational flexibility.

CytoGen, Inc. produced -5.61B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.82B in capital expenditures, free cash flow totaled -7.43B - equivalent to -321.68 per share.

Over the twelve months ended June 30, 2026, CytoGen, Inc. posted a gross margin of 24.42, reflecting its pricing power and cost economics. The operating margin of -21.44 and net profit margin of -38.52 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -10.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 7.44, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to CytoGen, Inc. shareholders.

CytoGen, Inc.'s most recent stock split took place on September 28, 2022 with a 1:3 split ratio.

As of June 30, 2026, CytoGen, Inc. has an Altman Z-Score of -0.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.